Late-break phase 3 REDUCE-2 data show clinically meaningful and durable serum urate reduction with pozdeutinurad

Summary

Detailed efficacy and safety results from the pivotal phase 3 study demonstrate statistically significant serum urate reductions over 12 months Pozdeutinurad is a single-day, highly selective investigational...